Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Investigation

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/JCI24394PMID 16284651PMCID PMC1280965
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

  2005cited by this paper
• Fitzpatrick's Dermatology in General Medicine.

  2004cited by this paper
• Inhibitory Fc Gamma Receptors: From Gene to Disease

  2004cited by this paper
• The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease.

  2004cited by this paper
• The Inhibitory Receptor FcγRII Reduces Joint Inflammation and Destruction in Experimental Immune Complex-Mediated Arthritides Not Only by Inhibition of FcγRI/III but Also by Efficient Clearance and Endocytosis of Immune Complexes

  2003cited by this paper
• The Role of Intramolecular Epitope Spreading in the Pathogenesis of Endemic Pemphigus Foliaceus (Fogo Selvagem)

  2003influential reference
• The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs1

  2003cited by this paper
• The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus.

  2003influential reference
• Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases.

  2003cited by this paper
• Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease.

  2003cited by this paper
• A systematic review of treatments for bullous pemphigoid.

  2002cited by this paper
• Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.

  2002cited by this paper
• Intravenous Immunoglobulin Mediates an Increase in Anti-Platelet Antibody Clearance via the FcRn Receptor

  2002cited by this paper
• Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype.

  2001cited by this paper
• A review of high‐dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders

  2001cited by this paper
• Therapy of pemphigus.

  2001cited by this paper
• Antibody-directed therapy: past, present, and future.

  2001cited by this paper
• IVIg inhibits reticuloendothelial system function and ameliorates murine passive‐immune thrombocytopenia independent of anti‐idiotype reactivity

  2001cited by this paper
• UvA-DARE ( Digital Academic Repository ) Accelerated autoantibody clearance by intravenous immunoglobulin therapy : studies in experimental models to determine the magnitude and time course of the effect

  2001cited by this paper
• Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

  2001cited by this paper
• Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

  2001cited by this paper
• Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid.

  2001cited by this paper
• Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations.

  2000cited by this paper
• Pemphigus Vulgaris Antibody Identifies Pemphaxin

  2000cited by this paper
• Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity.

  2000cited by this paper
• Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy

  2000cited by this paper
• Pemphigus vulgaris: the other half of the story.

  2000cited by this paper
• Modulation of Immune Complex–induced Inflammation In Vivo by the Coordinate Expression of Activation and Inhibitory Fc Receptors

  1999cited by this paper
• Pemphigus and bullous pemphigoid.

  1999cited by this paper
• Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases.

  1999cited by this paper
• Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.

  1998cited by this paper
• Immunosuppressive agents in dermatology. An update.

  1998cited by this paper
• Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

  1998cited by this paper
• Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies.

  1997cited by this paper
• Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases.

  1997cited by this paper
• A major role for neutrophils in experimental bullous pemphigoid.

  1997cited by this paper
• β2-microglobulin–deficient Mice Are Resistant to Bullous Pemphigoid

  1997cited by this paper
• Beta 2-microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism.

  1997cited by this paper
• Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells

  1997cited by this paper
• Mechanisms of action of intravenous immune globulin in immune‐mediated diseases

  1996cited by this paper
• Augmented humoral and anaphylactic responses in FcγRII-deficient mice

  1996cited by this paper
• The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.

  1996cited by this paper
• Localization of the site of the IgG molecule that regulates maternofetal transmission in mice

  1996cited by this paper
• Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice.

  1996cited by this paper
• Increased clearance of IgG in mice that lack β2‐microglobulin: possible protective role of FcRn

  1996cited by this paper
• New York, New York, USA

  1996cited by this paper
• Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice

  1996cited by this paper
• Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid.

  1995cited by this paper
• The role of complement in experimental bullous pemphigoid.

  1995cited by this paper
• Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus.

  1995cited by this paper
• Lichen planus pemphigoides: identification of 180 kd hemidesmosome antigen.

  1995cited by this paper
• A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus

  1994cited by this paper
• Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient.

  1993cited by this paper
• Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion.

  1993cited by this paper
• Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain.

  1993cited by this paper
• A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

  1993cited by this paper
• A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.

  1993cited by this paper
• Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg.

  1993cited by this paper
• Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura

  1993cited by this paper
• Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.

  1993cited by this paper
• The major cicatricial pemphigoid antigen is a 180-kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen.

  1992cited by this paper
• A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

  1992cited by this paper
• Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180.

  1992cited by this paper
• Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic.

  1992cited by this paper
• Treatment of systemic vasculitis with pooled intravenous immunoglobulin.

  1991cited by this paper
• Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains.

  1991cited by this paper
• β2-Microglobulin deficient mice lack CD4−8+ cytolytic T cells

  1990cited by this paper
• Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome.

  1990cited by this paper
• Isolation and characterization of the Fc receptor from the fetal yolk sac of the rat

  1990cited by this paper
• An Fc receptor structurally related to MHC class I antigens

  1989cited by this paper
• Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies.

  1988cited by this paper
• Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen.

  1988cited by this paper
• Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody

  1986cited by this paper
• Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody.

  1986cited by this paper
• Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer.

  1985cited by this paper
• High-dose intravenous gammaglobulin for myasthenia gravis.

  1984cited by this paper
• Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

  1984cited by this paper
• High-dose intravenous gammaglobulin for myasthenia gravis.

  1984cited by this paper
• Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease.

  1982cited by this paper
• Dermatology in general medicine

  1971cited by this paper

• Impact of Neonatal Fc Receptor on Transferrin Receptor Antibody Fusion Protein Pharmacokinetics.

  2026cites this paper
• Neonatal Fc Receptor - Biology and Therapeutics.

  2025cites this paper
• The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients.

  2025cites this paper
• Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceus.

  2025cites this paper
• Pemphigoid disease model systems for clinical translation

  2025cites this paper
• Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress

  2025cites this paper
• Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review

  2025cites this paper
• COVID-19-associated Autoimmune and Inflammatory Diseases: Molecular Mechanisms and the Role of IVIG Therapy

  2025cites this paper
• What is novel in the clinical management of pemphigus vulgaris?

  2024cites this paper
• Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives

  2024cites this paper
• FcRn inhibition reduces bullous pemphigoid anti-basement membrane zone IgG deposition and blistering in 3D human skin equivalents.

  2024cites this paper
• A rare case of progressive neonatal pemphigus vulgaris treated successfully with intravenous immunoglobulin

  2024cites this paper
• Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)

  2024cites this paper
• Immunoglobulins: Mechanistic Approaches in Moderation of Various Inflammatory and Anti-Inflammatory Pathways.

  2024cites this paper
• Immunomodulatory and anti‐inflammatory properties of immunoglobulin G antibodies

  2024cites this paper
• Does Intravenous Immunoglobulin Administration Affect the Clearance of Monoclonal Antibodies in Transplant Recipients?

  2024cites this paper
• Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation

  2023cites this paper
• Intravenous immunoglobulin in kidney transplantation: Mechanisms of action, clinical applications, adverse effects, and hyperimmune globulin.

  2023cites this paper
• Eosinophil-derived galectin-10 upregulates matrix metalloproteinase expression in bullous pemphigoid blisters.

  2023cites this paper
• The therapeutic age of the neonatal Fc receptor

  2023cites this paper
• Mouse models of pemphigus: valuable tools to investigate pathomechanisms and novel therapeutic interventions

  2023cites this paper
• Necrotizing Fasciitis—Severe Complication of Bullous Pemphigoid: A Systematic Review, Risk Factors, and Treatment Challenges

  2023influential citation
• Pemphiguserkrankungen: aktuelle und zukünftige Therapiekonzepte

  2023cites this paper
• Autoimmune blistering diseases: promising agents in clinical trials

  2023cites this paper
• Immunoglobulin G-dependent inhibition of inflammatory bone remodeling requires pattern recognition receptor Dectin-1.

  2023cites this paper
• Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview

  2022cites this paper
• Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?

  2022cites this paper
• Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system

  2022cites this paper
• Bullous pemphigoid—What do we know about the most recent therapies?

  2022cites this paper
• In Vitro, Ex Vivo, and In Vivo Models for the Study of Pemphigus

  2022cites this paper
• Immunotherapy for Pemphigus: Present and Future

  2022cites this paper
• Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities

  2022cites this paper
• Pemphigus Vulgaris: Present and Future Therapeutic Strategies

  2022cites this paper
• Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies

  2022cites this paper
• Continuing medical education

  2021cites this paper
• Multiple modes of action mediate the therapeutic effect of IVIg in experimental epidermolysis bullosa acquisita.

  2021cites this paper
• Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.

  2021cites this paper
• Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy

  2021cites this paper
• Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial *

  2021cites this paper
• The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies

  2021cites this paper
• Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment

  2021cites this paper
• Current Desensitization Strategies in Heart Transplantation

  2021cites this paper
• Neonatal Fc receptor induces intravenous immunoglobulin growth suppression in Langerhans cell histiocytosis

  2021cites this paper
• IgG4-Mediated Neurologic Autoimmunities

  2021cites this paper
• An Overview of Neonatal Lupus with Anti-Ro Characteristics

  2021cites this paper
• A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions

  2021cites this paper
• Intravenous immunoglobulin regulates anti-desmoglein 3 IgG production in B220- antibody-producing cells in mice with pemphigus vulgaris.

  2021cites this paper
• Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: implications from immunology, the FcRn pathway and clinical experience.

  2021cites this paper
• Next generation antibody-based therapies in neurology.

  2021cites this paper
• Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics

  2020cites this paper
• New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases

  2020cites this paper
• Treatment with anti‐neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice

  2020cites this paper
• New Therapeutic Horizons for Graves’ Hyperthyroidism

  2020cites this paper
• Global immunoglobulin supply: steaming towards the iceberg?

  2020cites this paper
• Novel Therapies for Pemphigus Vulgaris

  2020cites this paper
• An Update on the Pathogenesis of Skin Damage in Lupus

  2020cites this paper
• Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation

  2020cites this paper
• The role of novel therapeutic approaches for prevention of allosensitization and antibody‐mediated rejection

  2020cites this paper
• High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects

  2020cites this paper
• Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti‐C5 monoclonal antibody tesidolumab

  2020cites this paper
• Treatment of Necrotizing Soft Tissue Infections: IVIG.

  2020cites this paper
• Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease

  2020cites this paper
• Benefits and Risks of IgG Transplacental Transfer

  2020cites this paper
• N‐glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury

  2020cites this paper
• From bench to bedside: evolving therapeutic targets in autoimmune blistering disease

  2019cites this paper
• Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses

  2019cites this paper
• Immunoglobulin Therapy

  2019cites this paper
• Updates on diagnosis and management of autoimmune blistering diseases.

  2019cites this paper
• The use of IVIg in fetal and neonatal alloimmune thrombocytopenia- Principles and mechanisms.

  2019cites this paper
• The neonatal Fc receptor: Key to homeostasic control of IgG and IgG‐related biopharmaceuticals

  2019cites this paper
• Generation of two high affinity anti‐mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia

  2019cites this paper
• A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity.

  2019cites this paper
• Epidermolysis Bullosa Acquisita: The 2019 Update

  2019cites this paper
• Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer

  2019cites this paper
• High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease

  2019cites this paper
• Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models

  2019cites this paper
• Pemphigus: Current and Future Therapeutic Strategies

  2019cites this paper
• High‐dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft‐versus‐host disease

  2019cites this paper
• Bullous pemphigoid*

  2019cites this paper
• Treatment Update of Autoimmune Blistering Diseases.

  2019cites this paper
• Anti-inflammatory Activity of IgG-Fc.

  2019cites this paper
• Traitement du rejet humoral aigu

  2019cites this paper
• Editorial: Autoantibodies

  2019cites this paper
• The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership

  2019cites this paper
• Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid.

  2018cites this paper
• Mechanisms of Action and Immunomodulation by IVIg

  2018cites this paper
• Insight into small molecule binding to the neonatal Fc receptor by X-ray crystallography and 100 kHz magic-angle-spinning NMR

  2018cites this paper
• Modulatory effect of intravenous immunoglobulin on Th17/Treg cell balance in women with unexplained recurrent spontaneous abortion

  2018cites this paper
• Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration

  2018cites this paper
• Targeted Therapies for Autoimmune Bullous Diseases: Current Status

  2018cites this paper
• Immune modulation of i.v. immunoglobulin in women with reproductive failure

  2018cites this paper
• 36 – Maternal Immunization

  2018cites this paper
• Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181

  2018cites this paper
• EVIEW ullous Pemphigoid : Clinical Practice Guidelines

  2018cites this paper
• Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models.

  2018cites this paper
• Role of Intravenous Immunoglobulin in Dermatologic Disorders

  2018cites this paper
• Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica

  2018cites this paper
• Importance of recognition and improved treatment for antimelanoma differentiation‐associated protein 5‐associated dermatomyositis

  2017cites this paper
• Anti-idiotypic Antibodies against BP-IgG Prevent Type XVII Collagen Depletion

  2017cites this paper
• The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients

  2017cites this paper